Last reviewed · How we verify
NCT07132125
Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging
NA trial testing Default-style LLM chatbot in HPV Vaccination Intent in 930 participants. Completed in 22 May 2025.
22 May 2025
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 930 |
| Start date | 17 March 2025 |
| Primary completion | 22 May 2025 |
| Estimated completion | 22 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Default-style LLM chatbot
- Conversational-style LLM chatbot
- Public health informational materials
Conditions studied
- HPV Vaccination Intent — all drugs for HPV Vaccination Intent →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with HPV Vaccination Intent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to test whether short conversations with large language model (LLM) chatbots can persuade vaccine-hesitant parents to vaccinate their children against human papillomavirus (HPV). The study compares two chatbot styles to official public health information and to a no-message control. Parents of HPV-eligible children first complete a survey about their attitudes toward the HPV vaccine and their main concerns. They are then randomly assigned to read public health materials, have a three-minute conversation with either a default-style chatbot or a conversational-style chatbot tailored to their concern, or receive no message. The main outcome is change in intent to vaccinate immediately after the intervention, with follow-up surveys at 15 and 45 days.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Large Language Model Chatbot Conversations vs Public Health Materials and Parental HPV Vaccination Intentions: A Randomized Clinical Trial.
Sehgal NKR, Rai S, Tonneau M, Agarwal AK, et al · · 2026 · PMID 42258213 · DOI 10.1001/jamanetworkopen.2026.16822
Verify or expand the search:
- PubMed search for NCT07132125
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07132125 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07132125.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing